


GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro/Zepbound) have taken the world by storm. They help people lose significant amounts of weight by reducing appetite and quieting the constant “food noise” that so many struggle with.
But there’s a difficult truth emerging from the science: when people stop these drugs, they regain much of the weight they lost.
In fact, clinical trials show that within one year of stopping semaglutide, participants regained about two-thirds of the weight they had lost. Real-world data is even starker: by two years, 85% of patients have discontinued GLP-1 medications. By three years, fewer than 10% remain on them. And once the injections stop, hunger and cravings almost always return.